

1. (Twice Amended.) A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of :

- a) an amino acid sequence of SEQ ID NO:1,
- b) an amino acid sequence of SEQ ID NO:2
- c) a fragment of the amino acid sequence of SEQ ID NO:1 comprising at least 15 amino acids, wherein said fragment binds specifically with an anti-PGAMP-1 antibody,
- d) a fragment of the amino acid sequence of SEQ ID NO:1 comprising at least 15 amino acids, wherein said fragment binds specifically with an anti-PGAMP-1 antibody
- [, c) a naturally-occurring amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO:1,
- d) a naturally-occurring amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO:2,
- e) a biologically-active fragment of the amino acid sequence of SEQ ID NO:1,
- f) an antigenically-active fragment of the amino acid sequence of SEQ ID NO:1,
- g) a biologically-active fragment of the amino acid sequence of SEQ ID NO:2, and
- h) an antigenically-active fragment of the amino acid sequence of SEQ ID NO:2].

2. (Twice Amended.) A purified polypeptide [of claim 1] selected from the group consisting of:

- (a) a polypeptide having at least 90% amino acid sequence identity to SEQ ID NO:1 that binds specifically with an anti-PGAMP-1 antibody [retains at least one functional characteristic of the polypeptide of SEQ ID NO:1], and
- (b) a polypeptide having at least 90% amino acid sequence identity to SEQ ID NO:2 that binds specifically with an anti-PGAMP-2 antibody [and which retains at least one functional characteristic of the polypeptide of SEQ ID NO:2].

14. (Reiterated) A purified antibody which specifically binds to a polypeptide of claim 1.

15. (Reiterated) A purified agonist which specifically binds to and modulates the activity

of a polypeptide of claim 1.

16. (Reiterated) A purified antagonist which specifically binds to and modulates the activity of a polypeptide of claim 1.

17. (Reiterated) A method for treating or preventing a neoplastic disorder, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 16.

18. (Reiterated) A method for treating or preventing a reproductive disorder, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 16.

21. (Reiterated) A polypeptide of claim 1, having the amino acid sequence of SEQ ID NO:1 or SEQ ID NO: 2.

*D2*  
22. (Once Amended) A [pharmaceutical] composition comprising a polypeptide of claim 21 in conjunction with a suitable pharmaceutical carrier.

23. (Reiterated) An isolated polynucleotide selected from the group consisting of:  
a) a polynucleotide sequence of SEQ ID NO:3  
b) a polynucleotide sequence of SEQ ID NO:4,  
c) a naturally-occurring polynucleotide sequence having at least 90% sequence identity to the sequence of SEQ ID NO:3,  
d) a naturally-occurring polynucleotide sequence having at least 90% sequence identity to the sequence of SEQ ID NO:4 and  
e) a polynucleotide sequence complementary to a), b), c) or d).

24. (Reiterated) A method of detecting a target polynucleotide in a sample, said target polynucleotide having the sequence of a polynucleotide of claim 23, comprising